VRDN Viridian Pharma: Enterprise Value to EBITDA Ratio

viridiantherapeutics.com - graphic logo of issuer VRDN

The EV/EBITDA ratio chart with historical data provided by the GURU.Markets platform demonstrates the valuation dynamics of Viridian Therapeutics (VRDN), where the 0.00 mark indicates the valuation level. The biotech's prospects depend on antibody test outcomes and cost control. Environmental policy is limited to basic laboratory safety. The development of therapies for ocular pathologies is accelerating through partnerships with specialized medical centers.

Viridian Pharma - VRDN Company Value to EBITDA (period 11/23/2025 - 11/13/2026)

viridiantherapeutics.com (VRDN) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Price Viridian Pharma|VRDN - Average Forecast Price
- company stock capitalization data:
Market Valuation Viridian Corp|VRDN - Total Enterprise Value
- business book valuation details:
Book Value per Share Viridian Therapeutics|VRDN - Total Stockholders' Equity|Market Value to Book Value Ratio viridiantherapeutics.com|VRDN - Company Total Asset Base
- debt and liquidity data:
Total Debt to Equity Ratio Viridian Therapeutics|VRDN - Long-Term Debt to Equity|Short-Term Debt to Capital Viridian Therapeutics, Inc.|VRDN - Company Total Debt Obligations|Debt to Book Capitalization Ratio Viridian Corp|VRDN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Viridian Therapeutics|Quick Ratio viridiantherapeutics.com
- financial results and valuation multiples details:
VRDN - Company Profit|Projected Future Earnings Viridian Therapeutics|VRDN - Business Payback Period|Forward P/E Multiple Viridian Therapeutics|VRDN - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viridian Corp|VRDN - Operating profit before amortization|Net earnings per share for the last 12 months Viridian Therapeutics|VRDN - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months viridiantherapeutics.com|VRDN - Net earnings per one share growth for the current year|Earnings growth forecast for next year Viridian Therapeutics
Comprehensive company analysis:VRDN (Viridian Pharma)
Manufactured products of viridiantherapeutics.com

For Viridian Therapeutics (VRDN), which is developing a portfolio of antibodies for thyroid therapy, the current business EV/EBITDA multiple of 0.00 serves as an indicator of asset value relative to operating profit. This metric compares the company's Enterprise Value with its EBITDA, allowing investors to assess the efficiency of the capital-intensive model and determine the extent of the premium paid for the future potential of clinical trials.

Key competitors

EV/EBITDA Multiple ALC (Alcon Vision)|Bausch Health (BLCO) - Company Value to EBITDA|GKOS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA apellis.com|BLTE: EV/EBITDA Multiple|Company Value to EBITDA Ocular Therapeutix Inc (OCUL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harrow Health|LENZ Corp (LENZ) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio OCS (Oculis)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization EYPT (eyepointpharma.com)|EV/EBITDA Multiple KOD (Kodiak Sciences)|Total Company Value to Operating Income Before Depreciation Ratio Aldeyra Therapeutics Inc. (ALDX)|KALA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation IRD (Opus Genetics Inc)|OKYO: EV/EBITDA Multiple|ADVM - Total Company Value to Operating Income Before Depreciation Ratio|OTLK (Outlook Therapeutics, Inc.) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation CLSD (Clearside Biomedical Inc)|EV/EBITDA Multiple NBY|Total Company Value to Operating Income Before Depreciation Ratio kiorapharma.com|EV/EBITDA Multiple ALIM (Alimera Sciences, Inc.)|EV/EBITDA Multiple Eyenovia Inc. EYEN|GHSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OCUP (Ocuphire Pharma Inc) - Enterprise Value to Operating Income Before Depreciation|OPT (Opthea Ltd.) - Enterprise Value to EBITDA Ratio